Cold slurries used in medical applications typically comprise a partially frozen saline solution. Cold slurries are used in surgical applications to induce therapeutic hypothermia and slow organ and tissue metabolic rates thereby protecting a patient's organs during a surgical procedure. Cold slurries can also be injected into a patient for selective or non-selective cryotherapy and/or cryolipolysis.
Approaches to preparing and delivering a cold slurry to fat tissue through a cannula or needle are reported in International Application No. PCT/US2015/047292; U.S. patent application Publication No. 2013/0190744; and U.S. Provisional Application No. 62/416484, which are incorporated by reference herein in their entirety. An injectable cold slurry typically can have particle sizes ranging from 0.1 millimeters to 1.5 millimeters. The particles are generally globular in shape giving the cold slurry high fluidity. This allows the slurry to flow easily through a small diameter needle. In contrast, an ice slush consisting of dendritic crystals is difficult to inject without clogging.
A traditional approach to making an injectable cold slurry is to mix a saline solution with ice, crush it, and condition it prior to injection. The resulting cold slurry is then transferred to a syringe for injection. There are many challenges with this approach, including maintaining temperature, shape, and size of the cold slurry particles. As the slurry warms, the particles lose the desired shape and size. The problem of melting cold slurry is further exacerbated when a large amount of cold slurry needs to be delivered to many different areas. By the time the last injection of cold slurry is made, the cold slurry is markedly different than when first injected. Refreezing the cold slurry is not an option because doing so causes dendritic crystals to form that may clog the syringe needle.
The present invention provides methods and devices for making a cold slurry at a point of delivery. A point of delivery device delivers cold slurry components to a location at or near a target tissue. The components are combined to form the cold slurry at or near the point of delivery. This approach to generating a cold slurry at the point-of-delivery allows the characteristics of the cold slurry, such as temperature, particle shape and particle size, to be maintained and controlled
Point of delivery generation also allows cold slurry to be made on demand and on a continuous basis. This is particularly useful for treatment over an extended period of time during which melting can occur. The point of care, just-in-time slurry delivery of the invention delivers fresh cold slurry over an entire course of treatment obviating concerns over melting and slurry decomposition. The invention can also greatly reduce the cost and time associated with making cold slurry in batches.
One aspect of the invention comprises methods of making a cold slurry at or near a target tissue. Preferred methods include delivering components needed to make a cold slurry.
A first component can be water or a water mixture, such as water and glycerol. Cold slurry is formed at or near the target tissue as a result of interaction between the components. The delivery of components for making a cold slurry; and the formation of a cold slurry can occur continuously so that there is steady supply of fresh cold slurry at or near the target tissue.
Preferred ingredients for forming a cold slurry include liquid water and solid water. A surfactant, such as glycerol, can be added as well to enhance the fluidity of the cold slurry. Liquid water and the solid water are mixed to form a cold slurry at or near the target tissue. The solid water can be broken into particles that are mixed with the liquid water to form the slurry. Solid water (i.e., ice) can also be formed from another supply of liquid water that is subsequently frozen within the device.
The cold slurry can also be made at or near the target tissue from the nucleation of supercooled water with ice pellets (seeds). In this case the supercooled water is purified liquid water that has been “undercooled” below the freezing point of water. The supercooled water remains in liquid form due, in part, to its purity. When the supercooled water interacts with the ice pellets, it crystallizes and forms the cold slurry.
Methods of the invention are carried out using a point of delivery generation device. An exemplary device includes a first cannula for delivering a first component and a second cannula for delivering a second component to a target tissue. The first and second cannulas can be arranged side-by-side such that their respective outlets are more or less aligned to facilitate cold slurry formation. In some examples, the first and second cannulas each have a size and shape suitable for inserting through the subject's skin.
Cold slurry can also be made at or near a target tissue using a balloon. In a preferred embodiment, the balloon comprises an outer balloon and an inner balloon. The inner balloon is filled with liquid water supplied through, for example, a first delivery cannula. A space between the inner balloon and the outer balloon is filled with a cooling fluid or gas supplied through a second delivery cannula. This causes a cold slurry to form inside the inner balloon. The inner balloon can optionally be punctured (e.g., by a puncturing needle on the device) to release the cold slurry at or near the target tissue. In this example of the point of delivery generation device, the first delivery cannula and the second delivery cannula are arranged coaxially. The invention may also include a temperature sensor to measure the temperature of the cold slurry made at or near the target tissue. Other factors and aspects of the invention are provided in the following detailed description thereof.
Methods and devices of the invention comprise elements for point-of-care delivery of cold slurry to a tissue or organ. The invention obviates the need to pre-mix slurry prior to delivery, thus ensuring that fresh slurry (i.e., uncrystallized and at appropriate phase and temperature) is delivered for the duration of treatment and uniformly to all treatment areas. In a preferred embodiment, slurry is made in situ at a point of delivery in a patient. Components (reactants) used to generate the slurry are provided under conditions that result in the formation of a slurry at an appropriate temperature and of an appropriate consistency for a desired treatment protocol. In a highly-preferred embodiment, methods of the invention are provided subcutaneously to adipose tissue in order to cause reduction of the adipose tissue. Methods and devices of the invention can also be applied to cause reduction of visceral fat, or to reduce pain.
The point of delivery generation device 100 is used by inserting the application cannula 105 through the patient's skin and advancing the generating end 115 to a location at or near a target tissue or treatment site 120 (shown in phantom line). The target tissue 120 can, for example be subcutaneous adipose tissue. The cold slurry ingredients, such as liquid water, solid water, and glycerol, are pumped or otherwise conveyed, separately, from the supply 110, through the application cannula 105, and out the generating end 115. At the generating end 115, the components interact with each other and form the cold slurry 125 at or near the target tissue 120.
The cooling effect of the cold slurry 125 is localized to the target tissue 120 and possibly surrounding tissue, such as adjacent tissue 130. In this way, discomfort caused by the cold treatment is limited. The cold slurry is sterile and biocompatible; and, as such, the cold slurry 125 can be advantageously left in the body (e.g. no removal of the slurry is necessary after cooling has been effected).
The distal end of the first delivery cannula 305 is open forming a first outlet 340 for the first supply of liquid water 310 to exit. The distal end of the second delivery cannula 315 is open forming a second outlet 345 for the solid water 335 to exit. In front of the second outlet 345, there is a grinder (or vibrator) 350 to break the solid water 335 into particles as it emerges from the second delivery cannula 315. The outlets 340, 345 are arranged so that the first supply of liquid water 310 and the particles of solid water mix together to form a cold slurry.
The application cannula 105 further houses a second delivery cannula 415 for supplying ice pellets 420, which serves as nucleation sites for the crystallization process. The distal end of the first delivery cannula 405 is open and forms a first outlet 430 for the supercooled water 410 to exit. The distal end of the second delivery cannula 415 is open and forms a second outlet 435 for the ice pellets 420 to exit. The outlets 430, 435 are arranged so that the supercooled water 410 interacts with the ice pellets 420 causing it to crystalize and form a cold slurry.
The fluid delivery cannula 625 is open at its distal end defining a fluid outlet 630. The generating end 615 further includes an inner balloon 635 disposed around the fluid outlet 630. The fluid delivery cannula 625 is in fluid communication with an interior volume of the inner balloon 635, which is labeled 640 in the figure. The inner balloon 635 is located inside the outer balloon 620. As shown, the inner balloon 635 occupies a portion of the interior volume of the outer balloon 620 leaving a space or gap 645 between an outer wall of the inner balloon 635 (which is labeled 650 in the figure) and an inner wall of the outer balloon 620 (which is labeled 655 in the figure).
To generate a cold slurry at the point of delivery, the application cannula 605 is inserted through a patient's skin and the generating end 615 is advanced to a location at or near a target tissue in much the same manner as described above with reference to
Once the inner balloon 635 is filled with the cool fluid, the outer balloon 620 is filled with a cooling gas or fluid, such as liquid nitrogen. The cooling gas fills the gap 645 between the inner balloon 635 and the outer balloon 620. This causes the cool fluid in the inner balloon 635 to partial freeze and form a cold slurry 660, as shown in
This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Ser. No. 62/482,003 filed on Apr. 5, 2017, the entire disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3373906 | Hart et al. | Mar 1968 | A |
3893834 | Armstrong | Jul 1975 | A |
4619678 | Rubin | Oct 1986 | A |
4966601 | Draenert | Oct 1990 | A |
4983045 | Taniguchi | Jan 1991 | A |
4986079 | Koseki et al. | Jan 1991 | A |
5143063 | Fellner | Sep 1992 | A |
5304128 | Haber et al. | Apr 1994 | A |
5445523 | Fischer et al. | Aug 1995 | A |
5507790 | Weiss | Apr 1996 | A |
5769879 | Richards et al. | Jun 1998 | A |
6032675 | Rubinsky | Mar 2000 | A |
6041787 | Rubinsky | Mar 2000 | A |
6067803 | Wolsey et al. | May 2000 | A |
6244052 | Kasza | Jun 2001 | B1 |
6300130 | Toner et al. | Oct 2001 | B1 |
6324863 | Henry | Dec 2001 | B1 |
6334328 | Brill | Jan 2002 | B1 |
6403376 | Toner et al. | Jun 2002 | B1 |
6413444 | Kasza | Jul 2002 | B1 |
6428563 | Keller | Aug 2002 | B1 |
6430957 | Inada et al. | Aug 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6475212 | Dobak, III et al. | Nov 2002 | B2 |
6547811 | Becker et al. | Apr 2003 | B1 |
6575930 | Trombley, III et al. | Jun 2003 | B1 |
6673607 | Toner et al. | Jan 2004 | B2 |
6849072 | Lee et al. | Feb 2005 | B2 |
6962601 | Becker et al. | Nov 2005 | B2 |
7118591 | Frank et al. | Oct 2006 | B2 |
7276051 | Henley et al. | Oct 2007 | B1 |
7367341 | Anderson et al. | May 2008 | B2 |
7389653 | Kasza et al. | Jun 2008 | B2 |
7422601 | Becker et al. | Sep 2008 | B2 |
7507234 | Utley et al. | Mar 2009 | B2 |
7588547 | Deem et al. | Sep 2009 | B2 |
7603868 | Sveinsson | Oct 2009 | B2 |
7681411 | DiLorenzo | Mar 2010 | B2 |
7713266 | Elkins et al. | May 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
8117854 | Lampe et al. | Feb 2012 | B2 |
8192474 | Levinson | Jun 2012 | B2 |
8275442 | Allison | Sep 2012 | B2 |
8285390 | Levinson et al. | Oct 2012 | B2 |
8298216 | Burger et al. | Oct 2012 | B2 |
8308681 | Slocum et al. | Nov 2012 | B2 |
8337539 | Ting et al. | Dec 2012 | B2 |
8505315 | Kasza et al. | Aug 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8535275 | Salzman | Sep 2013 | B2 |
8603073 | Allison | Dec 2013 | B2 |
8608696 | DiMeo et al. | Dec 2013 | B1 |
8676338 | Levinson | Mar 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8808241 | DiMeo et al. | Aug 2014 | B2 |
8840608 | Anderson et al. | Sep 2014 | B2 |
8974451 | Smith | Mar 2015 | B2 |
9044212 | LePivert | Jun 2015 | B2 |
9078634 | Gonzales et al. | Jul 2015 | B2 |
9132031 | Levinson et al. | Sep 2015 | B2 |
9314368 | Allison et al. | Apr 2016 | B2 |
9345526 | Elkins et al. | May 2016 | B2 |
9375345 | Levinson et al. | Jun 2016 | B2 |
9398930 | Leung et al. | Jul 2016 | B2 |
9408745 | Levinson et al. | Aug 2016 | B2 |
9522031 | Anderson et al. | Dec 2016 | B2 |
9545523 | Nanda | Jan 2017 | B2 |
9585687 | Tenenbaum et al. | Mar 2017 | B2 |
9649220 | Anderson et al. | May 2017 | B2 |
9655770 | Levinson et al. | May 2017 | B2 |
9656056 | Boyden et al. | May 2017 | B2 |
9980765 | Avram et al. | May 2018 | B2 |
10174985 | Arnitz et al. | Jan 2019 | B2 |
10406021 | Wu et al. | Sep 2019 | B2 |
10500342 | Velis | Dec 2019 | B2 |
20010005338 | Muhlbauer et al. | Jun 2001 | A1 |
20020107199 | Walker | Aug 2002 | A1 |
20030012079 | Coffeen et al. | Jan 2003 | A1 |
20030032996 | Hallman | Feb 2003 | A1 |
20030074903 | Upadhye et al. | Apr 2003 | A1 |
20030171715 | Hommann et al. | Sep 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20040073280 | Dae et al. | Apr 2004 | A1 |
20040092883 | Casey et al. | May 2004 | A1 |
20040092920 | Rozenshpeer | May 2004 | A1 |
20040199115 | Rosenman | Oct 2004 | A1 |
20040220559 | Kramer et al. | Nov 2004 | A1 |
20050203598 | Becker et al. | Sep 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20060030843 | Lane et al. | Feb 2006 | A1 |
20060036302 | Kasza et al. | Feb 2006 | A1 |
20060122673 | Callister et al. | Jun 2006 | A1 |
20060161232 | Kasza et al. | Jul 2006 | A1 |
20060190066 | Worthen | Aug 2006 | A1 |
20070010861 | Anderson et al. | Jan 2007 | A1 |
20070056313 | Kasza et al. | Mar 2007 | A1 |
20070106247 | Burnett et al. | May 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20080045880 | Kjeken et al. | Feb 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080161772 | Nayak et al. | Jul 2008 | A1 |
20080195114 | Murphy | Aug 2008 | A1 |
20080236186 | Kasza et al. | Oct 2008 | A1 |
20080287839 | Rosen et al. | Nov 2008 | A1 |
20080300540 | Lewis | Dec 2008 | A1 |
20090012497 | Uber, III et al. | Jan 2009 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090030366 | Hoch | Jan 2009 | A1 |
20090071829 | O'Banion et al. | Mar 2009 | A1 |
20090118722 | Ebbers et al. | May 2009 | A1 |
20090125087 | Becker et al. | May 2009 | A1 |
20090149929 | Levinson et al. | Jun 2009 | A1 |
20090255276 | Kasza et al. | Oct 2009 | A1 |
20090270814 | Masi et al. | Oct 2009 | A1 |
20100036295 | Altshuler et al. | Feb 2010 | A1 |
20100081971 | Allison | Apr 2010 | A1 |
20100152824 | Allison | Jun 2010 | A1 |
20100152880 | Boyden et al. | Jun 2010 | A1 |
20100249753 | Gaisser et al. | Sep 2010 | A1 |
20100274184 | Chun | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20100308257 | Lampe et al. | Dec 2010 | A1 |
20100312202 | Henley et al. | Dec 2010 | A1 |
20110066216 | Ting et al. | Mar 2011 | A1 |
20110190751 | Ingle et al. | Aug 2011 | A1 |
20110238050 | Allison et al. | Sep 2011 | A1 |
20110238051 | Levinson et al. | Sep 2011 | A1 |
20110300079 | Martens et al. | Dec 2011 | A1 |
20120000217 | Gudnason | Jan 2012 | A1 |
20120022518 | Levinson | Jan 2012 | A1 |
20120055187 | Raines et al. | Mar 2012 | A1 |
20120167878 | Belzon et al. | Jul 2012 | A1 |
20120203312 | Batzer et al. | Aug 2012 | A1 |
20120239123 | Weber et al. | Sep 2012 | A1 |
20120289761 | Boyden et al. | Nov 2012 | A1 |
20130066309 | Levinson | Mar 2013 | A1 |
20130079684 | Rosen et al. | Mar 2013 | A1 |
20130116758 | Levinson et al. | May 2013 | A1 |
20130116759 | Levinson et al. | May 2013 | A1 |
20130158440 | Allison | Jun 2013 | A1 |
20130158636 | Ting et al. | Jun 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130245731 | Allison | Sep 2013 | A1 |
20130253496 | Anderson et al. | Sep 2013 | A1 |
20130319080 | Sezaki et al. | Dec 2013 | A1 |
20140005760 | Levinson et al. | Jan 2014 | A1 |
20140067025 | Levinson et al. | Mar 2014 | A1 |
20140091113 | Brewster et al. | Apr 2014 | A1 |
20140200511 | Boyden et al. | Jul 2014 | A1 |
20140257443 | Baker et al. | Sep 2014 | A1 |
20140277219 | Nanda | Sep 2014 | A1 |
20140277302 | Weber et al. | Sep 2014 | A1 |
20140303608 | Taghizadeh | Oct 2014 | A1 |
20140303696 | Anderson et al. | Oct 2014 | A1 |
20140303697 | Anderson et al. | Oct 2014 | A1 |
20140316393 | Levinson | Oct 2014 | A1 |
20140358079 | Fischell et al. | Dec 2014 | A1 |
20140378937 | Anderson et al. | Dec 2014 | A1 |
20150090769 | Lotsch | Mar 2015 | A1 |
20150112195 | Berger et al. | Apr 2015 | A1 |
20150141916 | Albrecht et al. | May 2015 | A1 |
20150216816 | O'Neil et al. | Aug 2015 | A1 |
20150297246 | Patel et al. | Oct 2015 | A1 |
20150320938 | King et al. | Nov 2015 | A1 |
20150328077 | Levinson | Nov 2015 | A1 |
20150342780 | Levinson et al. | Dec 2015 | A1 |
20150343156 | Fischell et al. | Dec 2015 | A1 |
20160051401 | Yee et al. | Feb 2016 | A1 |
20160058956 | Cohn et al. | Mar 2016 | A1 |
20160081974 | Lee et al. | Mar 2016 | A1 |
20160089550 | DeBenedictis et al. | Mar 2016 | A1 |
20160112195 | Jochheim et al. | Apr 2016 | A1 |
20160128767 | Azamian et al. | May 2016 | A1 |
20160175141 | Wu et al. | Jun 2016 | A1 |
20160184568 | Harris et al. | Jun 2016 | A1 |
20160242661 | Fischell et al. | Aug 2016 | A1 |
20160317621 | Bright | Nov 2016 | A1 |
20160354137 | Fischell et al. | Dec 2016 | A1 |
20160354237 | Gonzales et al. | Dec 2016 | A1 |
20170035603 | Kammer et al. | Feb 2017 | A1 |
20170051353 | Eng | Feb 2017 | A1 |
20170105869 | Frangineas, Jr. | Apr 2017 | A1 |
20170136237 | Eckhouse et al. | May 2017 | A1 |
20170143538 | Lee et al. | May 2017 | A1 |
20170164965 | Chang et al. | Jun 2017 | A1 |
20170202613 | Pellegrino et al. | Jul 2017 | A1 |
20170246032 | Gonzales et al. | Aug 2017 | A1 |
20170274011 | Garibyan et al. | Sep 2017 | A1 |
20170274078 | Garibyan et al. | Sep 2017 | A1 |
20170325992 | DeBenedictis et al. | Nov 2017 | A1 |
20180008500 | Anderson et al. | Jan 2018 | A1 |
20180116868 | Velis et al. | May 2018 | A1 |
20180140514 | Velis et al. | May 2018 | A1 |
20180289538 | Velis | Oct 2018 | A1 |
20180311079 | Garibyan et al. | Nov 2018 | A1 |
20190053939 | Garibyan et al. | Feb 2019 | A1 |
20190054242 | Velis | Feb 2019 | A1 |
20200046552 | Velis et al. | Feb 2020 | A1 |
20200086054 | Velis | Mar 2020 | A1 |
20200113627 | Alas et al. | Apr 2020 | A1 |
20200114041 | Alas et al. | Apr 2020 | A1 |
Number | Date | Country |
---|---|---|
102271741 | Dec 2011 | CN |
102307545 | Jan 2012 | CN |
103110473 | May 2013 | CN |
104010598 | Aug 2014 | CN |
105640706 | Jun 2016 | CN |
0418979 | Mar 1991 | EP |
0 445 951 | Sep 1991 | EP |
2 421 545 | Sep 2013 | ES |
2 338 428 | Dec 1999 | GB |
2003-500097 | Jan 2003 | JP |
2008-529663 | Aug 2008 | JP |
2009-539575 | Nov 2009 | JP |
2006086479 | Aug 2006 | WO |
2009086399 | Jul 2009 | WO |
2009089090 | Jul 2009 | WO |
2013036540 | Mar 2013 | WO |
2013113970 | Aug 2013 | WO |
2016033380 | Mar 2016 | WO |
2016033384 | Mar 2016 | WO |
2016054165 | Apr 2016 | WO |
2016090175 | Jun 2016 | WO |
2016138045 | Sep 2016 | WO |
2017196548 | Nov 2017 | WO |
2018187573 | Oct 2018 | WO |
Entry |
---|
Ash, 2003, Chronic peritoneal dialysis catheters: overview of design, placement, and removal procedures, Int Nephrol Dialysis 16(4):323-34. |
Brink, 2008, Abdominoplasty with direct resection of deep fat, Plast Reconstructive Surg 123(5):1597-1603. |
Ding, 2008, The association between non-subcutaneous adiposity and calcified coronary plaque: A substudy of the multi-ethnic study of atherosclerosis, Am J Clin Nutr 88(3):645-650. |
Fox, 2007, Abdominal visceral and subcutaneous adipose tissue compartments—association with metabolic risk factors in the Framingham heart study, Circulation 116:39-48. |
Garaulet, 2006, Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans, Int J Obes 30(6):899-905. |
Gradinger, 2005, Abdominoplasty, Chapter 83, pp. 2935-3026, in The art of aesthetic surgery: principles & techniques, Nahai, Ed., Quality Med Pub, St. Louis Mo. (92 pages). |
International Search Report & Written Opinion dated Aug. 29, 2018 for PCT/US2018/026273 (15 pages). |
International Search Report and Written Opinion dated Apr. 12, 2011, for PCT/US11/24766, filed Feb. 14, 2011 (11 pages). |
International Search Report and Written Opinion dated May 7, 2018, for PCT/US18/20387, filed Mar. 1, 2018 (7 pages). |
International Search Report and Written Opinion dated Jun. 11, 2018, for PCT/US2018/026260, filed Apr. 5, 2018 (6 pages). |
Laven, 2006, A pilot study of ice-slurry application for inducing laparoscopic renal hypothermia, BJU Int 99:166-70. |
Laverson, 2006, Improving abdominoplasty results: reconstruction of the linea alba sulcus by direct excision, Aesthetic Surg J 26:682-6. |
Stevens, 2014, Does cryolipolysis lead to skin tightening? A first report of cryodermadstringo, Aesth Surg J 34(6):NP32-NP34. |
Yamamoto, 2010, Adipose depots possess unique developmental gene signatures, Obesity 18(5):872-78. |
Extended European Search Report dated Dec. 9, 2020 in European Application No. 18781693.9. |
Search Report and Written Opinion dated Feb. 17, 2021 in Singapore Application No. 11201909303T, with English translation. |
Search Report and Written Opinion dated Feb. 8, 2021 in Singapore Application No. 11201909305P, with English translation. |
International Search Report and Written Opinion dated May 7, 2018, for PCT/US2018/20387, filed Mar. 1, 2018 (7 pages). |
Int Search Report & Written Op dated June 11, 2018, for PCT/US2018/026260, filed April 5, 2018 (6 pages) |
Esposito, 2016, Do you know this syndrome? Type 2 benign symmetric lipomatosis (Launois-Bensaude), Brazilian Annals of Dermatology 91:841. |
Gentile, 2016, Lipodystrophy in Insulin-Treated Subjects and other Injection-Site Skin Reactions: Are we Sure Everything is Clear?, Diabetes Therapy 7. |
International Preliminary Report on Patentability dated Aug. 21, 2012, for International application No. PCT/US2011/024766, filed Feb. 14, 2011 (8 pages). |
Int Search Report & Written Op dated Dec. 11, 2019, for PCT/US2019/054828, filed Oct. 4, 2019 (8 pages). |
Int Search Report & Written Op dated Dec. 23, 2019, for PCT/US2019/054834, filed Oct. 4, 2019 (10 pages). |
Int Search Report & Written Op dated Feb. 11, 2020, for PCT/US2019/055633, filed Oct. 10, 2019 (12 pages). |
Int Search Report & Written Op dated Jan. 2, 2020, for PCT/US2019/055605, filed Oct. 10, 2019 (9 pages). |
International Search Report and Written Opinion dated May 15, 2018, for PCT/US2017/059947, filed Nov. 3, 2017 (8 pages). |
Kanamori, 2015, “A case of an 8-year-old boy who was strongly suspected of suffering from familial angiolipomatosis”, J Pediatric Surg 3. |
Kosseifi, 2010, “Dercum's Disease: An Unusual Presentation”, Pain Medicine 11:1432. |
Lv, 2017, “A review of the postoperative lymphatic leakage”, Oncotarget 8:69069. |
Popescu, 2014, “Proteus Syndrome: a difficult diagnosis and management plan”, J Med and Life 7:1. |
Extended European Search Report dated Dec. 16, 2020 in European Application No. 18781069.2. |
Extended European Search Report dated Aug. 28, 2020 in European Application No. 17868153.2. |
Written Opinion dated Jul. 1, 2020 in Singapore Application No. 11201903946S. |
Office Action dated Mar. 1, 2021 in Chinese Application No. 2017800786800, with English translation. |
Number | Date | Country | |
---|---|---|---|
20180289537 A1 | Oct 2018 | US |
Number | Date | Country | |
---|---|---|---|
62482003 | Apr 2017 | US |